Nvidia’s Bold Move: Tackling Tech’s $1 Trillion Crisis

Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …

Find out details on these three critical Nvidia partners immediately.

Frederick G. Vogt net worth and biography

Frederick Vogt Biography and Net Worth

CEO of Iovance Biotherapeutics

Dr. Vogt joined Iovance in September 2016 as General Counsel. He has served as Interim CEO and President since May 2021 and a member of the board of directors since June 2024. He has more than 20 years of experience in the pharmaceutical and biopharmaceutical industries. Prior to joining Iovance, Dr. Vogt practiced law at the international firm of Morgan, Lewis & Bockius, focusing on intellectual property and business law in the life sciences and representing clients in patent strategy, transactional and litigation matters. Previously, he served in numerous scientific, management and legal roles of increasing responsibility over a period of 13 years at GlaxoSmithKline, where he focused primarily on oncology and cardiovascular drug development and made contributions to the development and approval of Hycamtin®️, Votrient®️, Tafinlar®️, and Mekinist®️. Dr. Vogt holds a B.S. in Chemistry from Ursinus College, a Ph.D. in Chemistry from Pennsylvania State University and a J.D. from Temple University. He has authored or co-authored more than 70 research papers and book chapters and is a co-inventor of numerous patent applications in the drug development and life sciences fields. He is admitted to practice in Pennsylvania and before the US Patent and Trademark Office, the US District Court for the Eastern District of Pennsylvania, and the US Court of Appeals for the Federal Circuit.

What is Frederick G. Vogt's net worth?: The estimated net worth of Frederick G. Vogt is at least $15,200.00 as of November 28th, 2022. Dr. Vogt owns 2,000 shares of Iovance Biotherapeutics stock worth more than $15,200 as of December 26th. This net worth estimate does not reflect any other investments that Dr. Vogt may own. Additionally, Dr. Vogt receives an annual salary of $1,390,000.00 as CEO at Iovance Biotherapeutics. Learn More about Frederick G. Vogt's net worth.
How old is Frederick G. Vogt?: Dr. Vogt is currently 50 years old. There are 4 older executives and no younger executives at Iovance Biotherapeutics. Learn More on Frederick G. Vogt's age.
What is Frederick G. Vogt's salary?: As the CEO of Iovance Biotherapeutics, Inc., Dr. Vogt earns $1,390,000.00 per year. Learn More on Frederick G. Vogt's salary.
How do I contact Frederick G. Vogt?: The corporate mailing address for Dr. Vogt and other Iovance Biotherapeutics executives is 999 SKYWAY ROAD SUITE 150, SAN CARLOS CA, 94070. Iovance Biotherapeutics can also be reached via phone at (650) 260-7120 and via email at [email protected]. Learn More on Frederick G. Vogt's contact information.
Has Frederick G. Vogt been buying or selling shares of Iovance Biotherapeutics?: Frederick G. Vogt has not been actively trading shares of Iovance Biotherapeutics during the last quarter. Most recently, on Monday, November 28th, Frederick G. Vogt bought 1,000 shares of Iovance Biotherapeutics stock. The stock was acquired at an average cost of $5.98 per share, with a total value of $5,980.00. Following the completion of the transaction, the chief executive officer now directly owns 2,000 shares of the company's stock, valued at $11,960. Learn More on Frederick G. Vogt's trading history.
Who are Iovance Biotherapeutics' active insiders?: Iovance Biotherapeutics' insider roster includes Iain Dukes (Director), Wayne Rothbaum (Director), and Frederick Vogt (CEO). Learn More on Iovance Biotherapeutics' active insiders.
Are insiders buying or selling shares of Iovance Biotherapeutics?: In the last twelve months, Iovance Biotherapeutics insiders bought shares 1 times. They purchased a total of 250,000 shares worth more than $2,287,500.00. In the last twelve months, insiders at the biotechnology company sold shares 1 times. They sold a total of 50,000 shares worth more than $503,000.00. The most recent insider tranaction occured on November, 12th when Director Ryan D Maynard sold 50,000 shares worth more than $503,000.00. Insiders at Iovance Biotherapeutics own 12.1% of the company. Learn More about insider trades at Iovance Biotherapeutics.
Information on this page was last updated on 11/12/2024.

Frederick G. Vogt Insider Trading History at Iovance Biotherapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/28/2022	Buy	1,000	$5.98	$5,980.00	2,000
6/1/2022	Buy	1,000	$6.44	$6,440.00	1,000

Frederick G. Vogt Buying and Selling Activity at Iovance Biotherapeutics

Iovance Biotherapeutics Company Overview

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Today's Range

Now: $7.60

$7.27

$7.63

50 Day Range

MA: $9.28

$7.22

$12.28

2 Week Range

Now: $7.60

$6.70

$18.33

Volume

6,158,471 shs

Average Volume

7,177,359 shs

Market Capitalization

$2.32 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.55

Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong

From Brownstone Research | Ad

Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.

Click here to watch this demo and decide for yourself.

Frederick Vogt Biography and Net Worth

What is Frederick G. Vogt's net worth?

How old is Frederick G. Vogt?

What is Frederick G. Vogt's salary?

How do I contact Frederick G. Vogt?

Has Frederick G. Vogt been buying or selling shares of Iovance Biotherapeutics?

Who are Iovance Biotherapeutics' active insiders?

Are insiders buying or selling shares of Iovance Biotherapeutics?